Psychodynamic Therapy: Modern Evidence Base, Short-Term vs Long-Term Formats, and Head-to-Head Comparison with CBT

Psychodynamic therapy (PDT) is one of the oldest formalized psychotherapeutic traditions, rooted in psychoanalytic theory but substantially modernized over the past century. Despite its historical prominence, PDT has faced persistent criticism regarding the strength of its empirical evidence base—criticism that has been partially addressed by a growing body of randomized controlled trials (RCTs), meta-analyses, and neuroimaging studies conducted since the early 2000s. The current landscape reveals a therapy modality with demonstrable efficacy for a range of psychiatric conditions, a distinctive theoretical framework emphasizing unconscious processes and relational patterns, and an evidence base that, while smaller than that of cognitive-behavioral therapy (CBT), is more robust than many clinicians and policymakers recognize.

Modern psychodynamic therapy encompasses a broad family of interventions unified by several core principles: the centrality of unconscious mental life, the role of early attachment experiences in shaping adult relational patterns, the therapeutic significance of transference and countertransference, and the importance of affect and its regulation in psychopathology. These principles are operationalized differently across short-term psychodynamic psychotherapy (STPP), typically 12–40 sessions, and long-term psychodynamic psychotherapy (LTPP), generally exceeding 50 sessions or lasting one year or more. This article examines the evidence base for both formats, explores the neurobiological mechanisms through which PDT exerts its effects, provides head-to-head comparisons with CBT, and identifies prognostic factors, comorbidity considerations, and current frontiers in research.

Psychodynamic therapy's theoretical framework has evolved substantially from classical Freudian drive theory. Contemporary psychodynamic approaches draw on object relations theory (Klein, Winnicott, Fairbairn), self psychology (Kohut), attachment theory (Bowlby), and relational psychoanalysis (Mitchell, Aron). Despite their differences, these traditions converge on several putative mechanisms of therapeutic change:

• Insight and self-understanding: Increasing conscious awareness of previously unconscious conflicts, wishes, fears, and defensive operations. The construct of psychological mindedness—the capacity to reflect on internal states—is both a predictor and outcome of therapy.
• Working through of core conflictual relationship themes (CCRTs): Luborsky's empirical operationalization of transference patterns demonstrated that patients tend to enact repetitive relational scripts. Change involves recognizing and modifying these patterns.
• Affect regulation and emotional experiencing: A central mechanism involves facilitating deeper emotional processing and expanding the patient's capacity to tolerate and integrate affects that were previously warded off by defensive processes.
• Internalization of the therapeutic relationship: The patient's experience of a secure, attuned therapeutic relationship is theorized to create new internal working models of attachment, effectively modifying implicit relational schemas.
• Reduction in defensive rigidity: Mature defenses (e.g., humor, sublimation, altruism) replace immature defenses (e.g., splitting, projection, acting out), a process measurable with instruments like the Defense Style Questionnaire (DSQ-40) and the Defense Mechanism Rating Scale (DMRS).

Importantly, process research has begun to empirically validate these mechanisms. Ablon and Jones's psychotherapy process Q-set research showed that sessions more closely conforming to a psychodynamic prototype—regardless of the therapist's stated orientation—predicted better outcomes in depression treatment. Similarly, research on sudden gains in psychodynamic therapy suggests that insight-related shifts, rather than cognitive restructuring, drive these therapeutic turning points.

An emerging neuroimaging literature has begun to elucidate the brain-level changes associated with psychodynamic therapy, challenging earlier claims that 'talk therapy' cannot produce meaningful neurobiological effects. While this literature is smaller than the corresponding CBT neuroimaging corpus, it reveals both shared and distinctive neural signatures of change.

Prefrontal-Limbic Circuitry

The dominant neurobiological model for psychodynamic therapy involves top-down and bottom-up regulation of the prefrontal cortex (PFC)–amygdala circuit. Psychodynamic therapy appears to strengthen connectivity between the medial prefrontal cortex (mPFC), including the ventromedial PFC and anterior cingulate cortex (ACC), and limbic structures including the amygdala and insula. Buchheim et al. (2012) conducted an fMRI study of 20 patients with recurrent major depressive disorder undergoing 15 months of psychoanalytic therapy. Using personalized attachment stimuli derived from the Adult Attachment Projective, they demonstrated significant reductions in limbic hyperactivation—particularly in the left anterior hippocampus, amygdala, and subgenual cingulate cortex—following treatment. These changes correlated with symptom improvement on the Hamilton Depression Rating Scale (HAM-D).

Default Mode Network (DMN) and Self-Referential Processing

The default mode network—comprising the mPFC, posterior cingulate cortex (PCC), precuneus, and angular gyrus—is critically involved in self-referential processing, autobiographical memory retrieval, and mentalizing. Psychodynamic therapy, with its emphasis on self-reflection and narrative coherence, is hypothesized to specifically modulate DMN function. Preliminary research suggests that successful PDT normalizes DMN connectivity patterns that are disrupted in depression (hyperconnectivity) and personality disorders (aberrant connectivity). This contrasts somewhat with CBT's more pronounced effects on dorsolateral PFC–amygdala top-down regulatory circuits, suggesting potentially distinct neural pathways of therapeutic action.

Neurotransmitter Systems

Direct evidence linking psychodynamic therapy to specific neurotransmitter changes is limited but suggestive. The serotonergic system (5-HT) is implicated via its role in emotional regulation and the subgenual ACC, a region rich in 5-HT1A receptors that shows consistent changes following PDT for depression. Karlsson et al. (2010) used PET imaging to demonstrate that psychodynamic therapy in patients with major depression was associated with increased serotonin 5-HT1A receptor binding in cortical and limbic regions, a finding paralleling the receptor changes seen with SSRI treatment. The dopaminergic reward system, centered on the ventral tegmental area (VTA)–nucleus accumbens pathway, may also be relevant, particularly in patients with anhedonic depression or personality pathology characterized by impaired reward processing.

Oxytocin, Attachment, and the Therapeutic Relationship

The oxytocin system is of particular theoretical interest given PDT's emphasis on the therapeutic relationship as a vehicle for change. Oxytocin, released during social bonding and attuned interpersonal contact, facilitates trust, reduces amygdala reactivity, and enhances mentalizing. While no study has directly measured oxytocinergic changes during psychodynamic therapy, the theoretical alignment is strong, and research on therapeutic alliance quality—which robustly predicts PDT outcomes—may partially reflect oxytocinergic mechanisms.

Epigenetic and Stress-System Changes

Psychotherapy research increasingly examines changes in the hypothalamic-pituitary-adrenal (HPA) axis and epigenetic markers. Patients with depression and PTSD show HPA axis dysregulation (elevated cortisol, blunted cortisol awakening response) and epigenetic modifications (e.g., methylation of the NR3C1 glucocorticoid receptor gene and FKBP5). While most psychotherapy epigenetic studies have used CBT protocols, the mechanisms are likely transdiagnostic. The Tavistock Adult Depression Study reported cortisol normalization in LTPP-treated patients with treatment-resistant depression, suggesting that long-term relational work can modulate chronic HPA axis dysregulation associated with early adversity.

Short-term psychodynamic psychotherapy (STPP) typically ranges from 12 to 40 sessions and includes several manualized variants: brief dynamic interpersonal therapy (DIT), intensive short-term dynamic psychotherapy (ISTDP; Davanloo), short-term anxiety-regulating psychotherapy, and supportive-expressive therapy (Luborsky). These share a time-limited frame, an active therapist stance, and a focus on a circumscribed dynamic focus or core conflict.

Major Depression

Driessen et al. (2015) conducted a large RCT (n = 341) comparing 16 sessions of STPP to 16 sessions of CBT for major depressive disorder. At post-treatment, CBT showed a modest advantage (response rates: CBT 39.8% vs. STPP 27.8%), but the difference narrowed at 6-month follow-up and was no longer significant at 12 months. A major Cochrane meta-analysis by Abbass et al. (2014) encompassing 33 RCTs and over 2,000 participants found STPP effective for depression, anxiety, and somatic symptom disorders, with a combined effect size (Hedges' g) of approximately 0.97 for depression at post-treatment relative to control conditions, and 1.51 at long-term follow-up—a notable finding suggesting that STPP's effects continue to grow after treatment termination, a pattern termed the sleeper effect.

Anxiety Disorders

Leichsenring et al. (2009) demonstrated in an RCT that STPP was non-inferior to CBT for generalized anxiety disorder, social anxiety disorder, and panic disorder, with response rates of approximately 50–57% for STPP across these conditions. For panic disorder specifically, Milrod et al. (2007) showed that panic-focused psychodynamic psychotherapy achieved a response rate of 73% compared to 39% in an applied relaxation control condition (n = 49), a clinically meaningful difference. The NNT for STPP versus control in anxiety disorders generally falls in the range of 3–5 depending on the specific condition and comparison group.

Somatic Symptom and Related Disorders

STPP, particularly ISTDP, has shown especially strong results for medically unexplained symptoms and somatic symptom disorders. Abbass et al. (2009) reported that ISTDP reduced emergency department utilization and healthcare costs significantly, with effect sizes (Cohen's d) of 0.83 for somatic symptoms. This is an area where STPP may hold a comparative advantage over CBT, given the psychodynamic model's emphasis on somatization as a defense against intolerable affect.

The Sleeper Effect

One of the most clinically significant findings in STPP research is the robust observation that treatment gains not only maintain but amplify after therapy ends. Shedler (2010), in his influential American Psychologist review, highlighted that this pattern—absent in most CBT outcome studies, which tend to show stable or slightly declining gains at follow-up—may reflect the internalization of therapeutic processes. The patient, having acquired new self-reflective capacities and modified internal working models, continues the therapeutic work autonomously. This finding has been replicated across multiple meta-analyses and represents a distinctive empirical signature of psychodynamic treatment.

Long-term psychodynamic psychotherapy (LTPP), defined as exceeding 50 sessions or one year of treatment, targets patients whose pathology is too entrenched, characterological, or comorbid for brief intervention. The evidence base for LTPP has grown substantially, though it remains constrained by the practical and ethical challenges of conducting long-term RCTs (patient attrition, difficulty maintaining control conditions for 1–3 years, cost).

Personality Disorders

The strongest evidence for LTPP comes from the treatment of personality disorders, particularly borderline personality disorder (BPD). Bateman and Fonagy's landmark studies of mentalization-based treatment (MBT)—a manualized psychodynamic approach—demonstrated striking results in patients with BPD. In their original RCT (1999, 2001), 18 months of partial hospitalization with MBT produced significant reductions in self-harm, suicide attempts, depressive symptoms, and inpatient days compared to treatment as usual. Crucially, 8-year follow-up data showed sustained superiority of MBT, with suicidality rates in the MBT group continuing to decline while the control group showed only modest improvement. Transference-focused psychotherapy (TFP; Clarkin, Yeomans, Kernberg) has also demonstrated efficacy in BPD, with an RCT showing TFP comparable to dialectical behavior therapy (DBT) on most outcomes and superior on measures of reflective functioning and attachment security.

The Tavistock Adult Depression Study

This landmark trial (Fonagy et al., 2015) randomized 129 patients with treatment-resistant depression (defined as having failed at least two adequate antidepressant trials) to 18 months of psychoanalytic psychotherapy (weekly sessions) plus treatment as usual (TAU) versus TAU alone. At the end of treatment, partial remission rates were modestly higher in the psychoanalytic group (30.3% vs. 24.0%). However, at 42-month follow-up, the psychoanalytic group showed a dramatic advantage: complete remission rates were 44.4% versus 10.3% for TAU alone. This long-term divergence in outcomes for a notoriously treatment-resistant population represents some of the most compelling evidence for LTPP and again illustrates the sleeper effect.

Meta-Analytic Evidence

Leichsenring and Rabung (2008, 2011) published meta-analyses of LTPP in complex mental disorders (defined as personality disorders, chronic mental disorders, or multiple comorbid conditions). Their analysis of 11 RCTs and 12 observational studies found a large overall effect size (Cohen's d = 1.8) for LTPP compared to shorter forms of psychotherapy. While these effect sizes have been debated—Smit et al. (2012) argued the estimates were inflated by methodological issues—subsequent re-analyses generally confirmed a moderate-to-large advantage for LTPP in complex presentations. De Maat et al. (2009) reported that LTPP achieved pre-post effect sizes of 0.78 for general symptoms and 0.94 for personality functioning across studies, with improvement rates of approximately 65% for target problems.

The comparison between PDT and CBT is arguably the most debated question in psychotherapy research. The answer is more nuanced than either camp typically acknowledges.

Acute-Phase Efficacy

For common mental disorders treated in short-term formats, the overall evidence suggests approximate equivalence between STPP and CBT, with some conditions favoring one approach. Cuijpers et al. (2020) conducted a comprehensive network meta-analysis of 385 psychotherapy trials for depression, finding that CBT and PDT were both effective compared to control conditions but that CBT showed a small advantage over PDT at post-treatment (standardized mean difference ≈ 0.10–0.20). Critically, this difference is below the threshold generally considered clinically meaningful and may reflect the fact that more CBT trials use disorder-specific protocols while PDT trials more often use generic approaches.

For bulimia nervosa, CBT is clearly superior to PDT, with specific CBT protocols (CBT-E) showing response rates of approximately 60% versus 20–30% for PDT. For depression in the context of personality pathology, however, PDT may hold an advantage. For PTSD, trauma-focused CBT and EMDR remain first-line, but Brom et al.'s (1989) early trial showed PDT comparable to systematic desensitization, and psychodynamic approaches have shown promise for complex PTSD with comorbid personality difficulties.

Long-Term Outcomes and the Temporal Pattern

The most consistent finding favoring PDT over CBT is the temporal trajectory of outcomes. Multiple studies and meta-analyses have demonstrated that PDT shows continued improvement at follow-up (the sleeper effect), while CBT tends to show stable gains or, in some studies, modest relapse. In the Driessen et al. (2015) depression trial, the initial post-treatment advantage for CBT had disappeared entirely by one-year follow-up. Town et al. (2017) reported similar crossover patterns in ISTDP for treatment-resistant depression.

Common Factors vs. Specific Factors

The Dodo Bird verdict—the hypothesis that all bona fide psychotherapies produce equivalent outcomes—is often invoked in this debate. Wampold's meta-analyses have consistently estimated that specific therapeutic techniques account for only about 1% of outcome variance, while common factors (alliance, empathy, positive regard) account for substantially more. However, this framing has been challenged by studies showing clear technique-specific advantages for CBT in OCD (ERP), specific phobias, and bulimia, and for PDT in personality disorders and chronic complex presentations. The more accurate conclusion is that relative efficacy depends substantially on the diagnosis, complexity, and chronicity of the presenting problem.

Cost-Effectiveness

Cost-effectiveness analyses present a complex picture. STPP and CBT are roughly equivalent in per-session and per-treatment costs for common mental disorders. LTPP is substantially more expensive in the short term but may be cost-effective for complex presentations when considering reduced healthcare utilization, disability costs, and productivity losses over multi-year time horizons. The Helsinki Psychotherapy Study found that long-term psychodynamic therapy produced greater cost savings at 5-year follow-up for patients with personality pathology compared to short-term therapy, driven primarily by reduced psychiatric hospitalizations and sick leave.

Treatment selection between PDT and other modalities should be guided by diagnostic factors, patient characteristics, and the complexity of the clinical presentation.

Strong Indications for PDT

• Personality disorders: Particularly BPD (via MBT, TFP), narcissistic personality disorder, and avoidant personality disorder. PDT is one of only a few evidence-based approaches for narcissistic pathology, for which no CBT manual has demonstrated comparable evidence.
• Chronic and treatment-resistant depression: The Tavistock study provides level-1 evidence for LTPP in treatment-resistant depression. PDT is especially indicated when depression is entangled with characterological issues, chronic interpersonal difficulties, and early adversity.
• Somatic symptom disorders: ISTDP has shown particularly strong effects for medically unexplained symptoms, conversion disorder, and chronic pain presentations with psychological underpinnings.
• Complex presentations with multiple comorbidities: Patients meeting criteria for a mood or anxiety disorder plus a personality disorder plus substance use or trauma history often benefit from PDT's integrative, formulation-driven approach over protocol-driven CBT.

Conditions Where CBT is Generally Preferred

• OCD: Exposure and response prevention (ERP) within a CBT framework has a substantially larger evidence base and higher response rates (approximately 60–70%) than any psychodynamic approach for OCD.
• Specific phobias: CBT-based exposure is the clear first-line treatment.
• Bulimia nervosa: CBT-E is the gold-standard treatment.
• Acute PTSD: Prolonged exposure and cognitive processing therapy have the strongest evidence.

Diagnostic Pitfalls

A common clinical error is offering PDT to patients who present with 'interesting' psychodynamic histories but whose actual disorder—such as OCD or a specific phobia—would respond more rapidly and reliably to CBT. Conversely, a frequent systemic error is offering brief, manualized CBT to patients with personality pathology, chronic relational difficulties, and treatment resistance, where dropout rates for CBT are high (30–50% in some BPD samples) and where PDT may provide a better therapeutic framework. Accurate diagnostic assessment, including personality disorder screening (e.g., SCID-5-PD, SIPP-118), is essential for appropriate treatment matching.

Research has identified several patient, therapist, and process variables that predict outcome in psychodynamic therapy.

Patient Factors Predicting Good Outcome

• Psychological mindedness: The capacity for self-reflection and interest in understanding one's internal life is among the strongest predictors of benefit from PDT. This has been measured with the Psychological Mindedness Assessment Procedure (PMAP) and correlates with treatment response.
• Quality of object relations (QOR): Patients with higher-quality, more mature interpersonal functioning—even if impaired—tend to respond better to interpretive, insight-oriented PDT. The QOR Scale predicts outcome across multiple STPP studies.
• Secure or preoccupied (rather than dismissing) attachment style: Patients with dismissing attachment may struggle to engage in the relational and exploratory aspects of PDT, at least in the early phases.
• Moderate symptom severity: Extremely high symptom severity (e.g., severe depression with psychotic features) predicts poorer response to PDT alone, typically requiring adjunctive pharmacotherapy.
• Motivation and capacity to form a therapeutic alliance: Early alliance quality (measured by session 3–5 on the Working Alliance Inventory) is one of the most robust pan-therapeutic predictors of outcome, accounting for approximately 5–8% of outcome variance.

Patient Factors Predicting Poor Outcome

• Active substance dependence: Active, untreated substance use disorders substantially compromise the capacity for introspection and emotional processing.
• Severe personality disorganization with low reflective functioning: Patients at the lower end of personality organization (Kernberg's psychotic personality organization) may require modified, more supportive approaches before expressive psychodynamic work is viable.
• Externalized coping style: Patients who predominantly externalize blame and show no interest in self-examination tend to benefit less from PDT than from structured, directive approaches.
• Absence of psychological distress: Paradoxically, some subjective distress appears necessary to motivate the difficult work of PDT.

Therapist Factors

Therapist competence and adherence to psychodynamic technique have been shown to predict outcome. The Comparative Psychotherapy Process Scale (CPPS) and adherence measures from the Penn Psychotherapy Project demonstrate that therapist skillfulness—particularly in the timing and accuracy of interpretations—significantly predicts outcome. Poorly timed or inaccurate transference interpretations can be harmful, associated with alliance ruptures and dropout. Training and supervision are critical moderators of PDT effectiveness.

Most patients seeking psychodynamic therapy present with significant comorbidity, which both influences treatment selection and moderates outcome.

Depression + Personality Disorder

Approximately 40–60% of patients with major depressive disorder in clinical settings meet criteria for at least one comorbid personality disorder, most commonly borderline, avoidant, dependent, or obsessive-compulsive PD. This comorbidity is associated with poorer acute-phase response to all treatments—pharmacological and psychotherapeutic—but may particularly favor PDT over CBT in the longer term. In the Tavistock study, patients with comorbid personality pathology were the ones who showed the most dramatic long-term benefit from psychoanalytic therapy relative to TAU.

Anxiety + Depression

Comorbid anxiety-depressive presentations are exceedingly common (up to 50–60% overlap in clinical samples). STPP trials have generally included these mixed presentations, and the Abbass et al. (2014) Cochrane review found STPP effective for both symptom clusters simultaneously. The psychodynamic model's transdiagnostic formulation approach—identifying underlying conflicts or relational themes that drive both anxious and depressive symptoms—may be particularly suited to these mixed presentations.

Trauma History and PTSD

A history of childhood adversity (emotional, physical, or sexual abuse; neglect; disorganized attachment) is present in an estimated 50–70% of patients with personality disorders and 30–50% of patients with treatment-resistant depression. PDT's emphasis on attachment and relational trauma makes it theoretically well-suited for these presentations. However, the evidence for PDT as a first-line PTSD treatment is weaker than for trauma-focused CBT. A phased approach—using PDT's strengths in stabilization, affect regulation, and relational repair before or alongside trauma processing—is often clinically indicated for complex PTSD.

Substance Use Disorders

Comorbid substance use affects 20–40% of patients with mood and anxiety disorders. Supportive-expressive therapy (Luborsky) has been tested in substance-using populations with modest positive results. However, active substance dependence generally requires concurrent addiction-focused treatment, and PDT is most effective when substance use is stabilized.

Several landmark studies have shaped the modern evidence base for psychodynamic therapy:

• The Menninger Psychotherapy Research Project (1954–1972): One of the earliest systematic attempts to study psychoanalytic and psychodynamic therapy outcomes. Though methodologically limited by modern standards, it generated foundational insights about the role of supportive versus expressive technique.
• The Penn Psychotherapy Project (Luborsky et al.): Developed supportive-expressive therapy and the Core Conflictual Relationship Theme method, providing some of the first empirical validation of psychodynamic constructs.
• Bateman & Fonagy MBT Trials (1999, 2001, 2009): Established MBT as an evidence-based treatment for BPD, with sustained gains at 8-year follow-up. These studies placed psychodynamic therapy for personality disorders on firm empirical ground.
• The Tavistock Adult Depression Study (Fonagy et al., 2015): Demonstrated LTPP's efficacy for treatment-resistant depression, with the dramatic long-term remission advantage representing perhaps the strongest single piece of evidence for LTPP.
• Milrod et al. Panic-Focused PDT Trial (2007): Showed that a manualized psychodynamic approach to panic disorder could achieve response rates comparable to or exceeding CBT in a rigorously designed RCT.
• The Helsinki Psychotherapy Study (Knekt et al., 2008, 2012): Compared short-term and long-term psychodynamic therapy with solution-focused therapy over a 5-year follow-up period (n = 326). Found that LTPP showed the slowest initial improvement but the best long-term outcomes, particularly for patients with personality pathology—a finding that crystallized the dose-response relationship in PDT.
• Shedler (2010) — "The Efficacy of Psychodynamic Psychotherapy" (American Psychologist): A pivotal narrative review that synthesized meta-analytic evidence and brought the sleeper effect finding to wide attention, challenging the prevailing assumption that CBT was the only empirically supported therapy for common mental disorders.

Despite significant advances, the psychodynamic evidence base faces several important limitations and has several active frontiers of investigation.

Limitations

• Smaller trial base: The number of RCTs for PDT remains substantially smaller than for CBT. As of 2023, CBT has been evaluated in over 700 RCTs for various conditions, while PDT has been studied in approximately 100–150 RCTs. This disparity reflects decades of differential funding more than differential efficacy, but it limits statistical power in meta-analyses.
• Heterogeneity of interventions: PDT encompasses a wide range of specific approaches (MBT, TFP, ISTDP, supportive-expressive, psychoanalytic), making aggregation across studies difficult and raising questions about what, exactly, is being tested.
• Allegiance effects: As with all psychotherapy research, researcher allegiance significantly moderates effect sizes. Studies conducted by PDT proponents tend to find results favoring PDT, and vice versa. Munder et al. (2013) estimated that allegiance effects account for a Cohen's d of approximately 0.30 in comparative outcome studies.
• Lack of dismantling studies: Very few studies have tested which specific components of PDT are active ingredients versus inert or redundant elements. The field lacks the component-analysis tradition common in CBT research.
• Underrepresentation of diverse populations: Most LTPP trials have been conducted in Northern European and North American settings with predominantly white, educated, middle-class samples. Generalizability to diverse populations and non-Western cultural contexts is uncertain.

Active Research Frontiers

• Neuroimaging of psychodynamic processes: Ongoing studies are using fMRI to examine changes in DMN connectivity, emotion regulation circuits, and mentalizing networks during and after PDT, with the aim of identifying neurobiological mediators of change.
• Precision psychiatry and treatment matching: Research is exploring whether specific patient characteristics (attachment style, reflective functioning, personality organization level) can be used to algorithmically match patients to PDT versus CBT, moving beyond the one-size-fits-all approach.
• Mechanisms of change research: Studies using intensive longitudinal methods (session-by-session measurement, experience sampling) are testing whether defense change, insight, and alliance rupture-repair sequences mediate outcome, as theorized.
• Digital and technology-assisted PDT: The COVID-19 pandemic accelerated research into videoconference-delivered psychodynamic therapy. Preliminary evidence suggests comparable alliance quality and outcomes to in-person delivery, though more research is needed for LTPP.
• Integration with pharmacotherapy: Research continues on optimal sequencing and combination of PDT with pharmacotherapy, particularly for treatment-resistant depression, where combined approaches may be superior to either alone.

The modern evidence base for psychodynamic therapy is more substantial and rigorous than commonly recognized. The following clinical summary reflects the current state of the literature:

• STPP (12–40 sessions) is an effective treatment for major depression, generalized anxiety disorder, social anxiety disorder, panic disorder, and somatic symptom disorders, with effect sizes comparable to CBT at post-treatment and potentially superior at long-term follow-up. Response rates typically range from 50–73% depending on the condition and specific protocol. NNT values relative to control conditions generally fall between 3 and 6.
• LTPP (>50 sessions) is the treatment of choice for personality disorders, chronic treatment-resistant depression, and complex presentations with multiple comorbidities. The strongest evidence supports MBT and TFP for BPD and psychoanalytic therapy for treatment-resistant depression. Effect sizes are large (d = 0.78–1.8), though the evidence base is smaller and methodologically more heterogeneous than for STPP.
• Compared to CBT, PDT shows roughly equivalent acute-phase efficacy for depression and anxiety, with potential advantages in long-term maintenance of gains. CBT is clearly preferred for OCD, specific phobias, bulimia nervosa, and acute PTSD. PDT is preferred for personality disorders, somatic symptom disorders, and complex, treatment-resistant presentations.
• Prognostic factors favoring PDT include psychological mindedness, higher quality of object relations, motivation for self-understanding, and the presence of identifiable relational patterns contributing to symptoms. Factors favoring CBT include preference for a structured approach, externalized coping style, specific symptom-focused goals, and lower chronicity.

The field is moving toward a more nuanced, patient-centered model of treatment selection that considers diagnosis, comorbidity, personality factors, and patient preference rather than reflexively defaulting to any single modality. Psychodynamic therapy, supported by a growing and increasingly rigorous evidence base, deserves a central place in this integrative clinical landscape.